Glaukos (NYSE:GKOS) CFO Sells $33,075.00 in Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 315 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total value of $33,075.00. Following the transaction, the chief financial officer owned 50,488 shares of the company’s stock, valued at $5,301,240. This represents a 0.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Glaukos Stock Performance

NYSE GKOS traded up $1.18 during trading hours on Wednesday, hitting $105.53. The company had a trading volume of 1,075,607 shares, compared to its average volume of 1,000,006. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09. The firm has a market cap of $6.06 billion, a P/E ratio of -68.53 and a beta of 0.81. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $163.71. The business has a fifty day simple moving average of $85.50 and a 200-day simple moving average of $91.61.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The company had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. The company’s revenue for the quarter was up 38.1% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Equities analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Hedge Funds Weigh In On Glaukos

Several hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its position in Glaukos by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock worth $54,645,000 after buying an additional 27,646 shares during the last quarter. CIBC Bancorp USA Inc. acquired a new position in shares of Glaukos in the 3rd quarter worth $486,000. CANADA LIFE ASSURANCE Co grew its holdings in shares of Glaukos by 0.8% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 61,348 shares of the medical instruments supplier’s stock worth $4,986,000 after acquiring an additional 514 shares during the last quarter. Verition Fund Management LLC purchased a new stake in shares of Glaukos during the third quarter valued at $579,000. Finally, Qube Research & Technologies Ltd lifted its holdings in shares of Glaukos by 87.2% during the third quarter. Qube Research & Technologies Ltd now owns 367,528 shares of the medical instruments supplier’s stock valued at $29,972,000 after purchasing an additional 171,163 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a report on Wednesday, October 8th. The Goldman Sachs Group started coverage on Glaukos in a research report on Wednesday, October 1st. They issued a “buy” rating and a $103.00 target price on the stock. UBS Group reiterated a “buy” rating and set a $140.00 price target on shares of Glaukos in a research report on Monday, November 10th. Zacks Research lowered Glaukos from a “strong-buy” rating to a “hold” rating in a report on Friday, August 15th. Finally, Mizuho set a $130.00 price objective on shares of Glaukos in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $119.08.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.